Insmed Incorporated licenses AZD 7986 from AstraZeneca for the treatment of non-CF bronchiectasis.
Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced a licensing agreement with AstraZeneca for global exclusive rights to AZD 7986, a novel oral inhibitor of dipeptidyl peptidase I (DPP1, also known as cathepsin C). Insmed has renamed the compound INS1007 and will pursue an initial indication of non-CF bronchiectasis.
Comment: The agreement provides AstraZeneca with the option to negotiate a future agreement with Insmed for commercialization of AZD7986/INS1007 in chronic obstructive pulmonary disease or asthma.
Comment: Non-CF (cystic fibrosis) bronchiectasis is a rare, progressive, neutrophil-driven pulmonary disorder in which the bronchi become permanently dilated due to chronic inflammation and infection.There is currently no cure for non-CF bronchiectasis.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.